Detailed financial statements for Femasys Inc. (FEMY): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering.
Analysis Summary
Femasys Inc. reported revenue of $2.3M in the most recent fiscal year, growing at a 5-year CAGR of 17.2%.
Balance sheet quality for FEMY: current ratio of 4.5, net cash position of $4.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $929064 | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Cost of Revenue | $223678 | $306533 | $370384 | $441938 | $380069 | $544903 | $872400 |
| Gross Profit | $705386 | $731385 | $809305 | $764280 | $691901 | $1.1M | $1.4M |
| Research & Development | $6.9M | $4.1M | $4.1M | $5.8M | $7.2M | $8.2M | $7.6M |
| Selling, General & Admin | $4.8M | $2.9M | $4.5M | $6.0M | $7.5M | $10.4M | $11.1M |
| Operating Expenses | $12.3M | $7.7M | $9.1M | $12.4M | $15.2M | $18.9M | $19.0M |
| Operating Income | -$11.6M | -$6.9M | -$8.3M | -$11.6M | -$14.5M | -$17.8M | -$17.6M |
| EBITDA | -$10.2M | -$5.8M | -$6.6M | -$10.5M | -$13.2M | -$16.3M | -$15.9M |
| Interest Expense | $9972 | $12553 | $19226 | $13464 | $165390 | $1.6M | $1.9M |
| Pre-tax Income | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Income Tax | $3006 | $1800 | $4000 | $6300 | $4338 | $9602 | $1297 |
| Net Income | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| EPS | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| EPS (Diluted) | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| Shares Outstanding (Diluted) | $588078 | $588078 | $590208 | $590208 | $769219 | $1.1M | $2.0M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.4M | $3.3M | $24.8M | $13.0M | $21.7M | $3.5M | $9.3M |
| Short-term Investments | $998831 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $83554 | $125790 | $84258 | $77470 | $98906 | $488373 | $616600 |
| Inventory | $172497 | $131378 | $208270 | $436723 | $667118 | $3.0M | $5.7M |
| Total Current Assets | $8.0M | $3.9M | $25.6M | $14.1M | $23.2M | $8.0M | $16.5M |
| Property, Plant & Equipment | $3.9M | $2.9M | $2.3M | $1.8M | $3.5M | $3.4M | $3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $160592 | $65069 | $25093 | $3294 | 0 | $65918 | $134914 |
| Total Assets | $12.6M | $7.6M | $28.6M | $16.9M | $27.8M | $12.4M | $20.7M |
| Accounts Payable | $481099 | $674333 | $445522 | $510758 | $1.1M | $1.4M | $1.8M |
| Short-term Debt | 0 | $630010 | $181123 | $141298 | 0 | $5.4M | 0 |
| Total Current Liabilities | $1.3M | $2.9M | $1.7M | $1.5M | $3.1M | $8.6M | $3.6M |
| Long-term Debt | 0 | $182490 | 0 | 0 | $4.3M | 0 | $3.2M |
| Total Liabilities | $58.0M | $4.1M | $2.2M | $1.7M | $9.4M | $10.1M | $14.9M |
| Retained Earnings | -$68.3M | -$75.2M | -$82.7M | -$94.1M | -$108.4M | -$127.2M | -$145.8M |
| Total Equity | -$45.4M | $3.5M | $26.3M | $15.2M | $18.4M | $2.3M | $5.9M |
| Total Debt | $1.7M | $2.1M | $990214 | $543715 | $6.7M | $7.4M | $4.7M |
| Net Debt | -$5.7M | -$1.3M | -$23.8M | -$12.4M | -$15.0M | $4.0M | -$4.6M |
| Working Capital | $6.8M | $974598 | $23.9M | $12.6M | $20.1M | -$560420 | $12.8M |
Cash Flow (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Income | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Depreciation & Amortization | $1.1M | $1.1M | $964287 | $889140 | $907985 | $872000 | $804281 |
| Stock-based Compensation | $358841 | $318640 | $193366 | $224939 | $675700 | $444147 | $790145 |
| Change in Working Capital | -$1.1M | $557962 | -$732716 | -$458267 | $1.2M | -$3.1M | -$2.1M |
| Operating Cash Flow | -$11.0M | -$4.9M | -$7.9M | -$10.7M | -$11.3M | -$19.4M | -$18.7M |
| Capital Expenditure | -$696499 | -$31681 | -$306868 | -$407475 | -$143917 | -$761706 | -$525007 |
| Acquisitions | $103141 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$11.7M | -$5.0M | -$8.2M | -$11.1M | -$11.4M | -$20.2M | -$19.2M |
Growth & Margins (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +11.7% | +13.7% | +2.2% | -11.1% | +52.0% | +40.8% | |
| Net Income Growth (YoY) | +38.7% | -9.0% | -51.2% | -25.0% | -32.1% | +1.0% | |
| EPS Growth (YoY) | +38.5% | -8.5% | -51.6% | +4.1% | +9.7% | +44.0% | |
| Shares Change (YoY) | +0.0% | +0.4% | +0.0% | +30.3% | +44.7% | +77.6% | |
| FCF Growth (YoY) | +57.6% | -65.9% | -35.2% | -2.6% | -76.9% | +4.9% | |
| Gross Margin | 75.9% | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Operating Margin | -1252.6% | -668.0% | -706.7% | -961.7% | -1353.4% | -1091.8% | -767.0% |
| EBITDA Margin | -1094.0% | -558.8% | -555.3% | -869.3% | -1228.5% | -1002.5% | -692.7% |
| Net Margin | -1213.3% | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
| FCF Margin | -1259.6% | -478.3% | -698.3% | -923.5% | -1065.7% | -1240.3% | -837.9% |
| Effective Tax Rate | -0.0% | -0.0% | -0.1% | -0.1% | -0.0% | -0.1% | -0.0% |
Per-Share Data (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF Per Share | $-19.90 | $-8.44 | $-13.96 | $-18.87 | $-14.85 | $-18.15 | $-9.72 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $588078 | $588078 | $590208 | $590208 | $769219 | $1.1M | $2.0M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Financial Health
| Piotroski F-Score | 3 |
| Altman Z-Score | -10.88 |
Key Ratios (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -12.50 | -20.34 | -6.09 | -0.93 | -1.05 | -1.31 | -1.23 |
| P/B | -3.11 | 40.01 | 1.75 | 0.70 | 0.82 | 10.63 | 3.88 |
| P/S | 151.91 | 135.98 | 39.02 | 8.81 | 13.99 | 15.04 | 9.93 |
| Gross Margin | 75.9% | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Operating Margin | -1252.6% | -668.0% | -706.7% | -961.7% | -1353.4% | -1091.8% | -767.0% |
| Net Margin | -1213.3% | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
Related companies: AIMD · APLM · BCTX · COCH · CRIS · DARE · EKSO
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of FEMY: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks